Dr. Reddy's announced the launch of Posaconazole delayed-release tablets, 100 mg, the therapeutic generic equivalent to Noxafil (posaconazole) delayed-release tablets, 100 mg approved by the U.S. Food and Drug Administration (USFDA).

The Noxafil brand and generic had U.S. sales of approximately US $ 140.8 million MAT for the most recent twelve months ending in February 2022 according to IQVIA.

Dr. Reddy's Posaconazole delayed-release tablets are available in 100 mg strength in bottle count sizes of 60.